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We describe outcomes after allogeneic transplantation in 34 patients with dyskeratosis congenita who
underwent transplantation between 1981 and 2009. The median age at transplantation was 13 years (range, 2
to 35). Approximately 50% of transplantations were from related donors. Bone marrow was the predominant
source of stem cells (24 of 34). The day-28 probability of neutrophil recovery was 73% and the day-100
platelet recovery was 72%. The day-100 probability of grade II to IV acute GVHD and the 3-year probability
of chronic graft-versus-host disease were 24% and 37%, respectively. The 10-year probability of survival was
30%; 14 patients were alive at last follow-up. Ten deaths occurred within 4 months from transplantation
because of graft failure (n ¼ 6) or other transplantation-related complications; 9 of these patients had
undergone transplantation from mismatched related or from unrelated donors. Another 10 deaths occurred
after 4 months; 6 of them occurred more than 5 years after transplantation, and 4 of these were attributed to
pulmonary failure. Transplantation regimen intensity and transplantations from mismatched related or
unrelated donors were associated with early mortality. Transplantation of grafts from HLA-matched siblings
with cyclophosphamide-containing nonradiation regimens was associated with early low toxicity. Late
mortality was attributed mainly to pulmonary complications and likely related to the underlying disease.
 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.edgments on page 1242.
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Table 1
Patient, Disease, and Transplantation Characteristics
Variable n (%)
No. of patients 34
Age at transplantation, yr
2 to 9 14 (41)
10 to 19 11 (32)
20 to 29 7 (21)
30 to 35 2 (6)
Sex
Male 28 (82)
Female 6 (18)
Performance score
<90% 10 (29)
90% to 100% 18 (53)
Not reported 6 (18)
Comorbid diseases
CMV infectionþpulmonary disease þliver disease 1 (3)
CMV infectionþpulmonary disease 1 (3)
CMV infection only 14 (41)
Comorbid not speciﬁed* 4 (12)
No comorbidity 14 (41)
Interval from DC diagnosis to transplantation,
median (range), mo
38 (4 to 214)
<12 10 (29)
12 to 23 2 (6)
24 to 35 3 (9)
36 to 60 7 (21)
>60 12 (35)
Conditioning regimens
Cyclophosphamide þ TBI  500 cGyy 6 (17)
TBI 200 cGy þ ﬂudarabine 3 (9)
Melphalanz þ ﬂudarabine 3 (9)
Busulfanx þ ﬂudarabine 1 (3)
Cyclophosphamide þ ﬂudarabine 4 (12)
Cyclophosphamide þ busulfan 6 (18)
Cyclophosphamide only 10 (29)
Not reported 1 (3)
Graft type
Bone marrow 24 (71)
Peripheral blood 7 (21)
Cord blood 3 (9)
Type of donor
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Dyskeratosis congenita (DC) is a rare, inherited, hetero-
geneous, multisystem disorder of bone marrow failure and
cancer susceptibility. Classical DC is characterized by the
clinical diagnostic triad of nail dystrophy, lacy reticular
pigmentation of the neck and upper chest, and oral leuko-
plakia [1]. Although the mucocutaneous triad may be subtle,
hematologic abnormalities are common, affecting approxi-
mately 80% to 90% of patients by 30 years of age.Mutations in
DC causative genes (TERT and TERC) have been detected in
subsets of patients with apparently acquired aplastic anemia
or myelodysplastic syndrome [1]. Bonemarrow failure (BMF)
is a common cause of premature death in patients with DC;
other causes of death include obstructive and interstitial
pulmonary complications and malignancies [2,3]. Patients
with DC have extremely short telomeres (< 1st percentile for
their age) because of germline defects in telomere biology
[4]. A germline mutation in a key telomere biology gene is
identiﬁed in approximately two thirds of DC families [1,5,6].
Telomeres consist of long TTAGGG nucleotide repeats and
a protein complex termed shelterin at chromosome ends;
they are essential for maintaining chromosomal stability [7].
Telomere length measurement by ﬂow cytometry with
ﬂuorescent in situ hybridization (ﬂow-FISH) in leukocyte
subsets is highly sensitive and speciﬁc for diagnosing DC [4].
BMF in patients with DC does not respond to immunosup-
pressive therapy [8]. Hematopoietic cell transplantation
(HCT) is currently the only modality with curative potential
for the bone marrow defect. No standard protocols are
available for HCT in DC patients but recent data suggest
successful engraftment and lower toxicity with reduced-
intensity protocols resulting in better overall short-term
survival [6,9-12]. In this review, we used data reported to
the Center for International Blood and Marrow Trans-
plantation Research (CIBMTR) to describe outcomes after
HCT in a larger cohort of patients with DC.HLA-identical sibling 16 (47)
Other relative 2 (6)
Matched unrelated donor 9 (26)
Mismatched unrelated donor 7 (21)
Graft-versus-host disease prophylaxis
Ex vivo T cell depletion 1 (3)
CD34 selection 1 (3)
Tacrolimus-containing 5 (15)
Cyclosporine-containing 26 (76)
Not reported 1 (3)
In vivo T cell depletion
Antithymocyte globulin 10 (29)
Alemtuzumab 3 (9)
None 15 (44)
Not reported 6 (18)METHODS
Data Source
The CIBMTR is a voluntary working group of more than 450 trans-
plantation centersworldwide that contribute patient, disease, transplantation,
and outcome information on allogeneic and autologous transplantations.
Participating centers report consecutive transplantations. Data are reported to
a Statistical Center at the Medical College of Wisconsin or the Data Coordi-
nating Center, National Marrow Donor Program, Minneapolis. Thirty-four
transplantations for DC were reported by 26 transplantation centers from
1981 to 2009 (32 transplantations occurred after 1989). The diagnosis of DC
was assigned by the transplantation center and BMF, the indication for
transplantation. The institutional review boards of the Medical College of
Wisconsin and the National Marrow Donor Program approved this study.Follow-up, surviving patients, median (range), mo 46 (3 to 116)
TBI indicates total body irradiation; CMV, cytomegalovirus.
* Other comorbid includes: organ impairment (n ¼ 1), external otitis,
peumocystis carinii pneumonia infection (n ¼ 1), and not speciﬁed (n ¼ 2).
y Doses cyclophosphamideþTBI 500 cGy: TBI dose 200 cGy (n¼ 3), 400
cGy (n ¼ 1), 450 cGy (n ¼ 1) and 500 cGy (n ¼ 1).
z Melphalan dose: 138 mg/m2, 72 mg/m2, 140 mg/m2.
x Busulfan dose: 3 mg/kg (n ¼ 1).End Points
The primary outcome was overall survival; death from any cause was
considered as an event and surviving patients were censored at last follow-
up. Other assessed outcomes were (1) neutrophil recovery, deﬁned as
achieving an absolute neutrophil count 0.5109/L for 3 consecutive days;
(2) platelet recovery, deﬁned as achieving a platelet count  20  109/L
independent of transfusions for 7 consecutive days; (3) acute (grade II to IV,
and III to IV) graft-versus-host disease (GVHD); and (4) chronic GVHD. Acute
and chronic GVHD were deﬁned according to standard criteria [13,14].Statistical Analysis
The probability of overall survival was calculated using the Kaplan-
Meier estimator [15]. Patients were followed from transplantation until
death or last contact for surviving patients. The probabilities of neutrophil
recovery, platelet recovery, and acute and chronic GVHD were calculated
using the cumulative incidence estimator, with death as the competing risk
[16]. Ninety-ﬁve percent conﬁdence intervals (CI) were generated using log
transformation. Analyses were performed using SAS version 9.3 (Carey, NC).RESULTS
Patient, disease, and transplantation characteristics are
shown in Tables 1, 2A and 2B. The median age at trans-
plantation was 13 years (range, 2 to 35). For over one-half of
transplantations, the interval between transplantation and
diagnosis of DC was greater than 3 years. Pretransplantation
comorbidities were reported for about 60% of trans-
plantations; cytomegalovirus (CMV) infection was the most
Table 2A
Characteristics of Patients Who Are Alive After Transplantation
Age at
Diagnosis, yr
Age at
Transplantation, yr
Yr of
Transplantation
Donor Source Conditioning Regimen GVHD Time to Last
Contact, mo
7.7 18.0 1992 HLA-matched sibling Busulfan þ cyclophosphamide Chronic 114.3
15.0 18.5 1997 HLA-matched sibling Cyclophosphamide Chronic 73
11.1 17.6 2000 HLA-matched sibling Cyclophosphamide None 82.2
19.4 21.7 2001 HLA-matched sibling Cyclophosphamide None 115.7
9.0 13.3 2006 Matched unrelated donor* Melphalan þ ﬂudarabine None 59.6
6.5 6.8 2007 HLA-matched sibling Cyclophosphamide Chronic 49.1
24.7 35.1 2007 Matched unrelated donor* Busulfan þ ﬂudarabine Chronic 60.4
6.6 13.7 2008 HLA-matched sibling* Cyclophosphamide None 3.32
1.1 3.2 2008 Matched unrelated donor TBI 200 cGy þ ﬂudarabine None 29.2
4.3 4.7 2008 Matched unrelated donor Cyclophosphamide ﬂudarabine None 38.7
4.1 9.4 2008 Matched unrelated donor TBI 200 cGy þ ﬂudarabine Chronic 39.8
1.7 2.3 2008 Matched unrelated donor Cyclophosphamide Chronic 43.2
19.4 19.9 2009 HLA-matched sibling* Cyclophosphamide þ ﬂudarabine Acute 12.5
4.4 4.8 2009 HLA-matched sibling Unknown None 37.4
GVHD indicates graft-versus-host disease.
* Peripheral blood progenitor cells; others received bone marrow.
S.M. Gadalla et al. / Biol Blood Marrow Transplant 19 (2013) 1238e12431240frequently reported comorbidity. Approximately 50% of
transplantations utilized grafts from a related donor. Bone
marrow was the predominant source of stem cells. Various
transplantation conditioning regimens were used. Nine
patients received total body irradiation (TBI) for 200 cGy
(n ¼ 5), 400 cGy (n ¼ 1), 450 cGy (n ¼ 1) or 500 cGy (n ¼ 1);
the dose was unknown in 1 patient. When cyclophospha-
mide was used with TBI, the dose was 200 mg/kg except for
1 patient who received low-dose TBI (200 cGy) and 50mg/kg
of cyclophosphamide. The remaining patients received
alkylating agents with or without ﬂudarabine (10 patients
received cyclophosphamide alone at 200 mg/kg; the donors
were HLA-matched siblings in 8 and unrelated individuals in
2). When cyclophosphamide was used with ﬂudarabine, the
dose was 120 mg/kg and with busulfan, 120 mg/kg or
200 mg/kg. In the 4 patients who received busulfan or
melphalan combined with ﬂudarabine, the busulfan dose
was < 6 mg/kg, and the melphalan dose < 150 mg/m2. The
median follow-up of surviving patients was 46 (range, 3 to
116) months.
Hematopoietic Recovery, GVHD, and Post-
Transplantation Malignancies
Thirty patients achieved neutrophil recovery, with
a cumulative incidence of 73% (95% CI, 53% to 85%) by day 28.
Four patients with primary graft failure died, 2 of them after
a second transplantation attempt. Among the 30 patients
with neutrophil recovery, 6 (20%) developed secondary graft
failure (4 died and 2 are surviving after second trans-
plantations at 2 and 4 months after the ﬁrst transplantation,
respectively). All but 1 graft failure occurred in recipients of
mismatched related or unrelated donor transplantations; the
transplantation conditioning regimens for these patients are
shown in Table 2B. The day-100 probability of platelet
recovery in the 25 evaluable patients was 72% (95% CI, 49% to
86%).
Eight patients developed acute GVHD (4 grade II, 1 grade
III, and 3 grade IV). The day-100 probability of acute GVHD
grades II to IV was 24% (95% CI, 11% to 39%). Eleven patients
developed chronic GVHD (4 limited, 6 extensive, and
1 unknown). Three of the 11 patients had a prior history of
acute GVHD. The 3-year probability of chronic GVHDwas 37%
(95% CI, 19% to 54%).
Three patients developed post-transplantation malig-
nancies: 1 Epstein-Barr viruseassociated lymphoprolifer-
ative disease (1 month after HCT at age 5 years; conditioningregimen, cyclophosphamide and ﬂudarabine with in vivo
T cell depletion); 1 squamous cell carcinoma of the skin
(4 months after HCT at age 22 years; conditioning regimen,
melphalan and ﬂudarabine; chronic GVHD onset, 4 months);
and 1 basal cell carcinoma of the skin (2 months after HCT at
age 35 years; conditioning regimen, busulfan and ﬂudar-
abine; chronic GVHD onset, 10 months). Although both
patients with skin cancer reported chronic GVHD, the onset
of chronic GVHD coincided or was after the onset of skin
cancer. Neither patient reported a history of acute GVHD.
Overall Survival
Twenty of the 34 patients (59%) died and 10 of these
deaths occurred during the ﬁrst 4 months after trans-
plantation. Not unsurprisingly, the 5-year probabilities of
overall survival were higher for the 21 patients who under-
went transplantation between 2000 and 2009 (65%, 95% CI,
40% to 82%) compared with the 11 patients who underwent
transplantation before 2000 (46%, 95% CI, 19% to 70%).
Tables 2A and 2B summarize the transplantation character-
istics of patients who are alive and deceased, respectively.
The most common causes of death were graft failure and
pulmonary failure/complications. Early deaths (n ¼ 10) were
attributed mainly to primary or secondary graft failure (n ¼
6). Eight early deaths occurred after unrelated donor trans-
plantations, 1 after a mismatched related donor transplant,
and 1 after an HLA-matched sibling donor transplantation.
Deaths beyond 4months (n¼ 10; 6 occurred beyond 5 years)
were attributed to pulmonary failure/complications (n ¼ 5),
GVHD (n ¼ 1), infection (n ¼ 1), and graft failure (n ¼ 2); in 1
patient, the cause of death was not reported. None of the
patients reported to have died from pulmonary failure were
reported to have had pulmonary disease at transplantation.
Notably, the use of cyclophosphamide alone for conditioning
was associated with the longest survival. It resulted in 1 early
death at 1.8 months after transplantation after an unrelated
donor transplantations, and 3 additional deaths attributed to
pulmonary complications occurred at 9,10, and 12 years after
transplantation, respectively. These very late events occurred
in recipients of HLA-matched sibling transplantations. The
1-, 5-, 10-, and 12-year probabilities of overall survival were
70%, 57%, 30%, and 15%, respectively (Figure 1).
DISCUSSION
In this retrospective study, we present a systematic
evaluation of HCT-related outcomes in patients with DC
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Figure 1. Probability of overall survival.
S.M. Gadalla et al. / Biol Blood Marrow Transplant 19 (2013) 1238e1243 1241reported to a transplantation registry. Published case reports
suggested high transplantation-related mortality and organ
toxicity in patients with DC [2]. Patients in the present study
had a slightly inferior survival compared with that reported
by Dietz et al., 57% versus 64% at 5-years [9]. This may be
explained in part by the fact that our study population
underwent HCT over a 20-year period and changes in
transplantation strategies, including donor selection and
supportive care, may have inﬂuenced survival. In our pop-
ulation who underwent transplantation between 2000 and
2009, we also observed a 5-year survival rate of 65% albeit in
21 patients. There was a predominance of male patients in
our study, which is likely because of the over-representation
of the X-linked form of the disease and the fact that about
20% of classic DC patients have a germline mutation in the X-
linked gene, DKC1. In the past decade, autosomal dominant
(TINF2, TERC, TERT, and RTEL1) and autosomal recessive
(NOP10, NHP2, WRAP53, TERT, RTEL1 and CTC1) genes leading
to DC have been recognized [1,5,6]. It is possible that in this
historical cohort, females with DC were underdiagnosed.
Despite improvement in transplantation outcomes in
many disorders, patients with DC still face signiﬁcant chal-
lenges; the 5-year post-transplantation survival probability
was only 57%. Our data suggest that DC patients receiving
low-intensity conditioning have fewer early adverse events
but continue to suffer from late severe outcomes (mainly
pulmonary toxicity, including ﬁbrosis). On the other hand,
high-dose conditioning regimens were associated with
severe organ toxicity and death, consistent with previously
published case reports [2]. The use of reduced-intensity
regimens has resulted in successful engraftment and lower
toxicity in several recent studies [9-12] and our observations
are consistent with these reports. But pulmonary ﬁbrosis
may develop in these patients at any time in the course of the
disease as part of disease pathogenesis. Germline mutations
in TERT or TERC can cause both apparently isolated aplastic
anemia and pulmonary ﬁbrosis. However, further evaluation
of family history often reveals features of a DC-related telo-
mere biology disorder. HCT is an effective treatment for DC
related bone marrow aplasia, but it doesn’t correct abnor-
malities related to the underlying genetic defects in DC. In
agreement with earlier reports [2,17], the high proportion of
death because of pulmonary causes in the current report
suggests that pulmonary complications may indeed be
accelerated after HCT. Pulmonary ﬁbrosis in patients with DC
may reﬂect cell apoptosis resulting from critically short
telomeres in rapidly dividing lung cells. Therefore, our data
S.M. Gadalla et al. / Biol Blood Marrow Transplant 19 (2013) 1238e12431242suggest that the optimal preparative regimen should be one
that minimizes pulmonary toxicity. It may also be prudent to
perform regular pulmonary function tests as a screening
tool for early diagnosis of pulmonary failure after HCT. Of
note, successful lung transplantation has been performed in
a patient with DC, but additional studies are required to
ascertain long-term outcomes.
In agreement with other reports [18,19], patients with
DC who received transplantations from HLA-identical
siblings had better overall survival. However, it is impor-
tant to note that because of signiﬁcant disease heteroge-
neity and the presence of silent carriers of disease-causing
mutations, all potential related donors must be carefully
evaluated for DC. We recommend all potential related
donors have mutation testing for the causative gene iden-
tiﬁed in the index patient. If the causative gene is unknown,
telomere length measurement by ﬂow-FISH should be
carried out to rule out occult DC in the potential related
donor. Needless to say, the presence of the causative gene
and/or short telomere length in apparently unaffected
family members bar these individuals from serving as
donors for patients with DC. An earlier case report [20]
described a complicated post-transplantation course
(delayed engraftment with long-lasting neutropenia and
death from sepsis approximately 6 month after trans-
plantation) in an adult patient who received HCT for an
apparent acquired severe aplastic anemia that was subse-
quently recognized as DC. The apparently healthy matched
sibling was a clinically silent carrier of the same germline
mutation; the sibling’s short telomeres and TERT mutation
were identiﬁed several years later [20].
Ten of the 34 patients in the present study did not engraft
or experienced late graft failure after primary engraftment.
Impaired engraftment in patients with DC might be
explained by altered cytokine expression and bone marrow
stromal cell function defects associated with telomere
dysfunction [21]. Late graft failure after primary engraftment
has been reported in association with short telomeres in 2
reported cases [22].
Three patients developed post-transplantation malig-
nancies, a complication that is not rare in transplantation
recipients [23]. However, it is important to note that the 2
solid cancers (squamous cell carcinoma of the skin and basal
cell carcinoma) reported here occurred very early after
transplantation, which is less common. Our data support
early surveillance for skin cancer in DC patients following
HCT. The occurrence of skin cancer may be explained by the
known high cancer risk in DC patients (reported to be 11-fold
higher than in the general population). This risk is greatest
for cancers of the tongue, acute myeloid leukemia, cancer of
the cervix, non-Hodgkin lymphoma, and basal cell carci-
noma of the skin [18]. It is noteworthy that both patients
with skin cancer were older, in their third and fourth decade,
and the occurrence of cancer may be a direct consequence of
the underlying diagnosis of DC rather than the trans-
plantation procedure. That said, the high cancer risk and
pulmonary complications in patients with DC call for inves-
tigation of HCT regimens customized speciﬁcally for DC; an
experience that proved successful in HCT for Fanconi anemia
patients [24]. Our data suggest that when the intensity of the
transplantation conditioning regimen is low, early mortality
is low, but these patients develop pulmonary complications
several years later, leading to their demise.
Our study is the largest to date and provides the ﬁrst
quantitative assessment of HCT outcomes in a sizable cohortof DC patients. However, it is limited by the lack of power to
evaluate predictors of outcomes because of limited sample
size, a variety of transplantation conditioning regimens, and
the biological heterogeneity of DC. Furthermore, under-
representation of DC patients with atypical clinical features
is expected. A larger collaborative study with well-deﬁned
clinical phenotypes and laboratory characterizations is
needed to validate and expand on our observations. In the
meantime, for DC patients with BMF, allogeneic HCT with
a suitably matched related or unrelated donor remains an
acceptable treatment option. The choice of transplantation
conditioning regimen is important, with regimens of lesser
intensity being favored. The data suggest long-term
surveillance is important, particularly for cancers and
pulmonary complications, both of which are likely to be
secondary to the genetic defect that is not corrected by HCT.
This is invaluable information when counseling patients and
families. It is also crucial to incorporate telomere length
measurements in the pretransplantation evaluation of
patients with apparently acquired severe aplastic anemia to
identify individuals with unrecognized DC and treat them
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